Table 1 Baseline characteristics in the whole population and according to systemic embolism events

From: Clinical characteristics and prognostic importance of anticoagulant use in ischemic left ventricular aneurysm: a retrospective cohort study

 

Overall N = 1043

Embolic events N = 75

Non-embolic events N = 968

P-value

Age, years

67.1 ± 12.0

67.7 ± 10.2

67.0 ± 12.1

0.570

Male

727 (69.7%)

54 (72.0%)

673 (69.5%)

0.698

BMI

23.4 ± 3.2

23.4 ± 3.1

23.4 ± 3.2

0.953

Smoking

307 (29.4%)

27 (36.0%)

280 (28.9%)

0.195

Drinking

144 (13.8%)

10 (13.3%)

134 (13.8%)

0.902

Prior atrial fibrillation

173 (16.6%)

19 (25.3%)

154 (15.9%)

0.051

Hypertension

574 (55.0%)

55 (73.3%)

519 (53.6%)

0.001

Diabetes mellitus

359 (34.4%)

36 (48.0%)

323 (33.4%)

0.012

Prior stroke/TIA

170 (16.3%)

31 (41.3%)

139 (14.4%)

<0.001

Prior major bleeding

23 (2.2%)

1 (1.3%)

22 (2.3%)

0.900

eGFR < 60 mL/min/1.73 m2

180 (17.3%)

13 (17.3%)

167 (17.3%)

1.000

Antithrombotic strategy

  APT only

684 (65.6%)

62 (82.7%)

622 (64.3%)

0.001

  Anticoagulant with or without APT

322 (30.9%)

10 (13.3%)

312 (32.2%)

<0.001

   Anticoagulant only

78 (7.5%)

2 (2.7%)

76 (7.9%)

0.157

   SAPT + anticoagulant

138 (13.2%)

3 (4.0%)

135 (13.9%)

0.023

   DAPT + anticoagulant

106 (10.2%)

5 (6.7%)

101 (10.4%)

0.400

   None

37 (3.5%)

3 (4.0%)

34 (3.5%)

0.917

Anticoagulant agent

  Warfarin

73 (7.0%)

2 (2.7%)

71 (7.3%)

0.127

  NOAC

195 (18.7%)

6 (6.7%)

189 (12.8%)

0.014

   Rivaroxaban 2.5 mg bid

46 (4.4%)

0 (0%)

46 (4.8%)

0.053

   Rivaroxaban 10 mg qd

112 (10.7%)

5 (6.7%)

107 (11.1%)

0.237

   Rivaroxaban 15 mg qd

15 (1.4%)

0 (0%)

15 (1.5%)

0.278

   Dabigatran 110 mg bid

22 (2.1%)

1 (1.3%)

21 (2.2%)

0.627

  Unfractionated heparin

54 (5.2%)

2 (2.7%)

52 (5.4%)

0.308

Other drugs

  Beta-blockers

648 (62.1%)

43 (57.3%)

605 (62.5%)

0.374

  RAAS inhibitors

596 (57.1%)

45 (60.0%)

551 (56.9%)

0.604

  Diuretic agents

617 (59.2%)

44 (58.7%)

573 (59.2%)

0.929

  Spironolactone

501 (48.0%)

33 (44.0%)

468 (48.3%)

0.545

  1. Values are n, mean ± SD, n (%), or median (interquartile range). All statistical tests were two-sided at a significance level of 0.05.
  2. BMI body mass index, TIA transient ischemic attack, eGFR estimated glomerular filtration rate, APT anti-platelet therapy, SAPT single anti-platelet therapy, DAPT dual anti-platelet therapy, NOAC novel oral anticoagulant, RAAS rein-angiotensin-aldosterone system.
Back to article page